Tesofensine vs Oxyntomodulin
Head-to-head comparison of Tesofensine (Tesofensine (NS2330)) and Oxyntomodulin (Endogenous glucagon-like peptide 1 and glucagon co-agonist peptide) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Tesofensine | Oxyntomodulin |
|---|---|---|
| Category | Weight Management | Weight Management |
| Full Name | Tesofensine (NS2330) | Endogenous glucagon-like peptide 1 and glucagon co-agonist peptide |
| Molecular Weight | 426.52 g/mol | ~4,200 Da |
| Half-Life | ~200-300 hours | 12-15 minutes |
| Amino Acids | Small molecule | 37 |
| Typical Dose | — | Research doses vary; commonly 100-300 mcg in small human studies |
| Route | — | Subcutaneous/IV |
| Purity | >98% | ≥98% |
| Studies Count | 35 | 80 |
| Research Status | Phase III Clinical Trials | Clinical |
Tesofensine Benefits
- ✓Potent appetite suppression, increased metabolic rate, enhanced thermogenesis, improved mood during dieting, reduces food reward-seeking behavior
Oxyntomodulin Benefits
- ✓reduces appetite
- ✓increases satiety
- ✓supports weight loss
- ✓improves postprandial metabolic signaling
Tesofensine Dosing
Clinical doses: 0.25-1.0 mg orally once daily. Research typically uses 0.5 mg. Extremely long half-life (8-13 days) means steady-state in 7-10 days.
Oxyntomodulin Dosing
Research-only dosing|Subcutaneous or IV administration in trials|Pair with calorie restriction and monitoring
Tesofensine Side Effects
- ⚠Dry mouth, insomnia, constipation, increased heart rate, elevated blood pressure. Not recommended with uncontrolled hypertension.
Oxyntomodulin Side Effects
- ⚠nausea
- ⚠GI discomfort
- ⚠decreased appetite beyond target
Research Overview
Tesofensine
Phase II trials showed 12.8 kg average weight loss at 1.0 mg dose over 6 months. Simultaneously inhibits reuptake of norepinephrine, dopamine, and serotonin, producing appetite suppression and increased thermogenesis.
Oxyntomodulin
Human studies showed acute reductions in food intake and modest weight loss, helping establish the GLP-1 and glucagon co-agonism concept. It remains a foundational peptide for obesity and satiety research.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.